Michael Burkes Brophy Sells 25,931 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 25,931 shares of the company’s stock in a transaction on Wednesday, January 22nd. The stock was sold at an average price of $164.97, for a total transaction of $4,277,837.07. Following the transaction, the chief financial officer now owns 109,665 shares of the company’s stock, valued at $18,091,435.05. This represents a 19.12 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Michael Burkes Brophy also recently made the following trade(s):

• On Thursday, October 31st, Michael Burkes Brophy sold 1,866 shares of Natera stock. The shares were sold at an average price of $126.45, for a total value of $235,955.70.
• On Monday, October 28th, Michael Burkes Brophy sold 1,238 shares of Natera stock. The stock was sold at an average price of $118.21, for a total transaction of $146,343.98.
• On Friday, October 25th, Michael Burkes Brophy sold 691 shares of Natera stock. The stock was sold at an average price of $118.81, for a total value of $82,097.71.

Natera Stock Performance

Shares of NASDAQ:NTRA traded up $4.47 during trading on Wednesday, reaching $171.93. The company had a trading volume of 2,052,001 shares, compared to its average volume of 1,460,392. Natera, Inc. has a fifty-two week low of $62.96 and a fifty-two week high of $183.00. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23. The stock’s fifty day moving average price is $165.35 and its 200 day moving average price is $135.41. The firm has a market capitalization of $22.70 billion, a price-to-earnings ratio of -97.69 and a beta of 1.65.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.31. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The company had revenue of $439.80 million for the quarter, compared to analysts’ expectations of $361.43 million. During the same period in the previous year, the company posted ($0.95) EPS. Natera’s revenue was up 63.9% compared to the same quarter last year. As a group, equities research analysts predict that Natera, Inc. will post -1.61 EPS for the current year.

Hedge Funds Weigh In On Natera

A number of large investors have recently made changes to their positions in the stock. Blue Trust Inc. boosted its position in Natera by 104.3% during the fourth quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock worth $30,000 after purchasing an additional 97 shares in the last quarter. Quarry LP grew its stake in Natera by 148.4% in the 2nd quarter. Quarry LP now owns 318 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 190 shares during the last quarter. Versant Capital Management Inc increased its holdings in Natera by 345.8% during the 4th quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 166 shares in the last quarter. Covestor Ltd raised its position in Natera by 34.3% during the third quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock worth $47,000 after acquiring an additional 95 shares during the last quarter. Finally, GAMMA Investing LLC grew its position in shares of Natera by 32.7% in the third quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock valued at $55,000 after purchasing an additional 106 shares during the last quarter. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on NTRA. Piper Sandler lifted their price target on shares of Natera from $150.00 to $200.00 and gave the company an “overweight” rating in a research report on Monday, November 18th. Robert W. Baird lifted their price objective on shares of Natera from $120.00 to $160.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. Leerink Partners upped their price target on Natera from $140.00 to $150.00 and gave the stock an “outperform” rating in a report on Thursday, October 17th. Sanford C. Bernstein lifted their price objective on shares of Natera from $160.00 to $200.00 and gave the stock an “outperform” rating in a research report on Friday, January 10th. Finally, Canaccord Genuity Group increased their price target on shares of Natera from $165.00 to $180.00 and gave the company a “buy” rating in a research note on Friday, January 3rd. One analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $160.63.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.